Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invicta DiagnosticNSE:INVICTA +3.88%22 Interest Coverage is 12.05 as of Mar. 2026, which is 64% below its 10-year median of 33.36. GuruFocus rates NSE:INVICTA with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 92 Medical Diagnostics & Research companies, Invicta Diagnostic ranks better than 70.65% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Invicta Diagnostic's
Operating Income
for the
six
months ended in Mar. 2026 was ₹11.2 Mil. Invicta Diagnostic's Interest Expense for the
six
months ended in Mar. 2026 was ₹-0.9 Mil.
Invicta Diagnostic's interest coverage for the quarter that ended in Mar. 2026 was 12.05.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Invicta Diagnostic's Interest Coverage or its related term are showing as below:
NSE:INVICTA'
s Interest Coverage Range Over the Past 10 Years
Min: 29.14 Med: 33.36 Max: 87.4
Current: 33.36
NSE:INVICTA's Interest Coverage is ranked better than 70.65% of 92
companies
in the Medical Diagnostics & Research industry
Industry Median: 10.09
vs NSE:INVICTA: 33.36
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Invicta Diagnostic Interest Coverage Related Terms
Invicta Diagnostic Interest Coverage Historical Data
* Premium members only.
The historical data trend for Invicta Diagnostic's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Invicta Diagnostic Interest Coverage Chart
Invicta Diagnostic Annual Data
Trend
Mar24
Mar25
Mar26
Interest Coverage
87.40
29.14
33.36
Invicta Diagnostic Semi-Annual Data
Mar24
Mar25
Sep25
Mar26
Interest Coverage
N/A
N/A
52.62
12.05
NSE:INVICTA vs TMO, DHR, IDXX: Interest Coverage Comparison
For the Diagnostics & Research subindustry, Invicta Diagnostic's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invicta Diagnostic Interest Coverage vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invicta Diagnostic's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Invicta Diagnostic's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invicta Diagnostic (NSE:INVICTA) has a Interest Coverage of 12.05 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Invicta Diagnostic and its competitors. This is 64% below median its historical median of 33.36. Over the past decade, Invicta Diagnostic's Interest Coverage has ranged from 29.14 to 87.40. According to the industry distribution chart, Invicta Diagnostic ranks #27 out of 92 companies in the Medical Diagnostics & Research industry, placing it in the top 29.3%.
Is Invicta Diagnostic's Interest Coverage too high?
Invicta Diagnostic's current Interest Coverage of 12.05 is 64% below median its 10-year median of 33.36. Over the past 10 years, this metric has ranged from a low of 29.14 to a high of 87.40. The Medical Diagnostics & Research industry median Interest Coverage is 10.09. Invicta Diagnostic's value of 12.05 is 19.4% above this industry median. Based on the distribution chart, Invicta Diagnostic ranks #27 out of 92 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Invicta Diagnostic has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Invicta Diagnostic's Interest Coverage compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Invicta Diagnostic ranks #27 out of 92 companies for Interest Coverage. This puts Invicta Diagnostic in the upper half of its industry. The industry median Interest Coverage is 10.09. Invicta Diagnostic's value of 12.05 is 19.4% above this benchmark. Historically, Invicta Diagnostic's own Interest Coverage has ranged from 29.14 to 87.40 over the past decade. While the company's 10-year median is 33.36 vs. the industry median of 10.09, Invicta Diagnostic has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Diagnostics & Research company?
The median Interest Coverage among Medical Diagnostics & Research companies is 10.09, based on 92 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Invicta Diagnostic's current Interest Coverage of 12.05 is 19.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Invicta Diagnostic and its competitors. For the Medical Diagnostics & Research industry, the median Interest Coverage is 10.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invicta Diagnostic's current Interest Coverage is 12.05, which is 64% below median its own 10-year median of 33.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invicta Diagnostic stock overvalued right now?
Invicta Diagnostic (NSE:INVICTA) has a current Interest Coverage of 12.05. The current Interest Coverage is 12.05, which is 64% below median its 10-year median of 33.36 and 19.4% above the Medical Diagnostics & Research industry median of 10.09. Invicta Diagnostic's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Invicta Diagnostic (NSE:INVICTA), the current Interest Coverage is 12.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invicta Diagnostic Ltd is engaged in the business of medical and diagnostic services and operates diagnostic centres providing medical testing and allied healthcare services in the Mumbai Metropolitan Region. The Company runs a diagnostic chain comprising seven diagnostic centres and one centralised laboratory across MMR in Maharashtra and operates under a hub and spoke model with a flagship hub in Thane, additional hub centres, spoke centres, and a centralised laboratory. Its service offerings include radiology and imaging, pathology and clinical laboratory tests, teleradiology, and services such as ultrasound, X Ray, CT scan, MRI scan, PET scan, and cardiac diagnostics, with patient convenience supported through home sample collection, house calls, and multiple report delivery options.
22GF Score
Get the complete analysis for NSE:INVICTA
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INVICTA has been successfully added to your 
